图书馆订阅: Guest
环境病理学,毒理学和肿瘤学期刊

每年出版 4 

ISSN 打印: 0731-8898

ISSN 在线: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma

卷 36, 册 2, 2017, pp. 151-158
DOI: 10.1615/JEnvironPatholToxicolOncol.2017018341
Get accessGet access

摘要

Lung cancer is responsible for 1.6 million deaths. Approximately 80%−85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach−surgery, chemotherapy, radiotherapy, and/or immunotherapy−is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-specific molecules and signaling pathways and thus has more limited nonspecific toxicities. This approach targets the epidermal growth factor receptor (EGFR, HER-1/ErbB1), a receptor tyrosine kinase of the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. Because EGFR is expressed at high levels on the surface of some cancer cells, it has been recognized as an effective anticancer target. EGFR-targeted therapies include monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors. Tyrosine kinases are an especially important target because they play an important role in the modulation of growth factor signaling. This review highlights various classes of synthetically derived molecules that have been reported in the last few years as potential EGFR-TK inhibitors (TKIs) and their targeted therapies in NSCLC, along with effective strategies for overcoming EGFR-TKI resistance and efforts to develop a novel potent EGFR-TKI as an efficient target of NSCLC treatment in the foreseeable future.

对本文的引用
  1. Zheng Yuan-Yuan, Xiao Rong, Zhang Lu-Xin, Yan Hui-Jie, Wang Ji-Hong, Lv Li, A Novel Mutant of rLj-RGD3 (rLj-112) Suppressed the Proliferation and Metastasis of B16 Cells through the EGFR Signaling Pathway, Marine Drugs, 17, 2, 2019. Crossref

  2. Hoang Tung, Myung Seung-Kwon, Pham Thu Thi, Kim Jeongseon, Ju Woong, Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials, Journal of Clinical Medicine, 9, 4, 2020. Crossref

  3. Wang Meng-na, Kuang Yun, Gong Li-ying, Hua Ye, Pei Qi, Guo Cheng-xian, Cao Yu, Huang Jie, Yang Guo-ping, First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects, Investigational New Drugs, 38, 6, 2020. Crossref

  4. Yuan Yuan , Wang Yonggang , Liu Zimei , Sun Yong , Yao Yang , Yu Wenxi , Shen Zan , MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen, International Journal of Oncology, 2019. Crossref

  5. Zhang Ding, Song Dongli, Shi Lin, Sun Xiaoru, Zheng Yonghua, Zeng Yiming, Wang Xiangdong, Mechanisms of interactions between lung‐origin telocytes and mesenchymal stem cells to treat experimental acute lung injury, Clinical and Translational Medicine, 10, 8, 2020. Crossref

  6. Dai Yuemei , Wang Wenran , Sun Qingchao , Tuohayi Jiazina , Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines, Experimental and Therapeutic Medicine, 2018. Crossref

  7. Tchelebi Leila T, Batchelder Emma, Wang Ming, Lehrer Eric J, Drabick Joseph J, Sharma Navesh, Machtay Mitchell, Trifiletti Daniel M, Zaorsky Nicholas G, Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies, JNCI Cancer Spectrum, 5, 4, 2021. Crossref

  8. Lu Min, Liu Bin, Xiong Hui, Wu Fang, Hu Chunhong, Liu Ping, Trans ‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in NSCLC s via suppressing MAPK /Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498 , Journal of Cellular and Molecular Medicine, 23, 4, 2019. Crossref

  9. Zhang Zhirui, Zhang Mengxiao, Liu Hao, Yin Wu, AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells, Journal of Cellular Biochemistry, 120, 1, 2019. Crossref

  10. Ge X, Zhang Y, Huang F, Wu Y, Pang J, Li X, Fan F, Liu H, Li S, EGFR tyrosine kinase inhibitor Almonertinib induces apoptosis and autophagy mediated by reactive oxygen species in non-small cell lung cancer cells, Human & Experimental Toxicology, 40, 12_suppl, 2021. Crossref

  11. Wang Jia-li, Chen Chuan-sheng, Jia Zhi-rong, Miao Li-yun, Xie Jun, Pan Zhen-zhen, Duan Ya-lei, Liu Shuo, Hou Meng-jun, Ding Xuan-sheng, Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations, Journal of Cancer Research and Clinical Oncology, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain